ADAPTIVE BIOTECHNOLOGIES CORPORATION Deferred Revenue Recognized
ADAPTIVE BIOTECHNOLOGIES CORPORATION (ADPT) reported Deferred Revenue Recognized of $19.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Income Statement › Other Income
us-gaap:ContractWithCustomerLiabilityRevenueRecognized · last filed 2026-08-04
- ADAPTIVE BIOTECHNOLOGIES CORPORATION contract with customer, liability, revenue recognized for the quarter ending 2026-03-31 was $8.20M.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION contract with customer, liability, revenue recognized for the quarter ending 2025-03-31 was -$16.86M.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION contract with customer, liability, revenue recognized for the quarter ending 2024-03-31 was -$13.20M.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION contract with customer, liability, revenue recognized for the quarter ending 2023-03-31 was -$18.09M.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION contract with customer, liability, revenue recognized for fiscal 2025 was -$105.33M.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION contract with customer, liability, revenue recognized for fiscal 2024 was -$62.41M.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION contract with customer, liability, revenue recognized for fiscal 2023 was -$73.76M.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION contract with customer, liability, revenue recognized for fiscal 2022 was -$99.36M.
| Period end | Contract with Customer, Liability, Revenue Recognized 0 month | Contract with Customer, Liability, Revenue Recognized | Contract with Customer, Liability, Revenue Recognized 3 month | Contract with Customer, Liability, Revenue Recognized 3 month as first filed | Contract with Customer, Liability, Revenue Recognized 6 month | Contract with Customer, Liability, Revenue Recognized 9 month | Contract with Customer, Liability, Revenue Recognized 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $19.00M 10-Q · filed 2026-08-04 | ||||||
| 2026-03-31 | $8.20M 10-Q · filed 2026-05-05 | ||||||
| 2025-12-31 | $68.30M 10-K · filed 2026-02-26 | -$105.33M 10-K · filed 2026-02-26 | |||||
| 2025-09-30 | $63.40M 10-Q · filed 2025-11-05 | -$87.06M 10-Q · filed 2025-11-05 | |||||
| 2025-06-30 | $22.50M 10-Q · filed 2025-08-05 | -$35.17M 10-Q · filed 2025-08-05 | |||||
| 2025-03-31 | $12.10M 10-Q · filed 2025-05-01 | -$16.86M 10-Q · filed 2025-05-01 | |||||
| 2024-12-31 | $35.90M 10-K · filed 2025-03-03 | -$62.41M 10-K · filed 2025-03-03 | |||||
| 2024-09-30 | $27.40M 10-Q · filed 2024-11-07 | -$45.28M 10-Q · filed 2024-11-07 | |||||
| 2024-06-30 | $18.40M 10-Q · filed 2024-08-01 | -$28.52M 10-Q · filed 2024-08-01 | |||||
| 2024-03-31 | $10.50M 10-Q · filed 2024-05-07 | -$13.20M 10-Q · filed 2024-05-07 | |||||
| 2023-12-31 | $53.20M 10-K · filed 2024-02-29 | -$73.76M 10-K · filed 2024-02-29 | |||||
| 2023-09-30 | $41.20M 10-Q · filed 2023-11-09 | -$53.87M 10-Q · filed 2023-11-09 | |||||
| 2023-06-30 | $28.70M 10-Q · filed 2023-08-02 | -$36.36M 10-Q · filed 2023-08-02 | |||||
| 2023-03-31 | $15.00M 10-Q · filed 2023-05-03 | -$18.09M 10-Q · filed 2023-05-03 | |||||
| 2022-12-31 | $77.30M 10-K · filed 2023-02-14 | -$99.36M 10-K · filed 2023-02-14 | |||||
| 2022-09-30 | $58.00M 10-Q · filed 2022-11-03 | -$72.01M 10-Q · filed 2022-11-03 | |||||
| 2022-06-30 | $34.50M 10-Q · filed 2022-08-03 | -$43.55M 10-Q · filed 2022-08-03 | |||||
| 2022-03-31 | -$19.72M 10-Q · filed 2022-05-04 | ||||||
| 2021-12-31 | $75.70M 10-K · filed 2022-02-15 | -$95.79M 10-K · filed 2022-02-15 | |||||
| 2021-09-30 | $36.70M 10-Q · filed 2021-11-03 | -$73.06M 10-Q · filed 2021-11-03 | |||||
| 2021-06-30 | $40.60M 10-Q · filed 2021-08-04 | -$47.88M 10-Q · filed 2021-08-04 | |||||
| 2021-03-31 | $19.00M 10-Q · filed 2021-05-05 | $16.00M 10-Q · filed 2022-05-04 | -$21.35M 10-Q · filed 2021-05-05 | ||||
| 2020-12-31 | $61.60M 10-K · filed 2021-02-24 | -$69.82M 10-K · filed 2021-02-24 | |||||
| 2020-09-30 | -$47.14M 10-Q · filed 2020-11-10 | ||||||
| 2020-06-30 | -$30.00M 10-Q · filed 2020-08-10 | ||||||
| 2020-03-31 | $13.10M 10-Q · filed 2020-05-12 | -$14.12M 10-Q · filed 2020-05-12 | |||||
| 2019-12-31 | $8.50M 10-K · filed 2020-02-26 | -$50.62M 10-K · filed 2020-02-26 | |||||
| 2019-09-30 | $6.40M 10-Q · filed 2019-11-12 | $36.04M 10-Q · filed 2019-11-12 | |||||
| 2019-06-30 | $4.40M 10-Q · filed 2019-08-13 | $19.34M 10-Q · filed 2019-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |